Skip to main content

Advertisement

SpringerLink
Log in

Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease

  • Original Article—Liver, Pancreas, and Biliary Tract
  • Published:
Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Background

Accurately evaluating liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) is important for identifying those who may develop complications. The aims of this study were (1) to measure serum Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA+-M2BP) using the glycan sugar chain-based immunoassay and (2) to compare the results with clinical assessments of fibrosis.

Methods

Serum WFA+-M2BP values were retrospectively evaluated in 289 patients with NAFLD who had undergone liver biopsy. Histological findings were evaluated by three blinded, experienced liver-specific pathologists.

Results

For stages 0 (n = 35), 1 (n = 113), 2 (n = 49), 3 (n = 41), and 4 (n = 51) of liver fibrosis, the serum WFA+-M2BP cutoff indexes were 0.57, 0.70, 1.02, 1.57, and 2.96, respectively. Multivariate regression analysis showed that serum WFA+-M2BP values were associated with the stage of fibrosis (≥stage 2). The areas under the receiver operating characteristic curve (AUROC), sensitivity, and specificity of serum WFA+-M2BP were 0.876, 85.9, and 74.6 %, respectively, for severe fibrosis (≥stage 3) and were 0.879, 74.6, and 87.0 %, respectively, for cirrhosis. When compared with six non-invasive conventional markers, serum WFA+-M2BP had the greatest AUROC for diagnosing severe fibrosis and cirrhosis.

Conclusions

Serum WFA+-M2BP values are useful for assessing the stage of liver fibrosis in patients with NAFLD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221–31.

    Article  CAS  PubMed  Google Scholar 

  2. Bhala N, Usherwood T, George J. Non-alcoholic fatty liver disease. BMJ. 2009;339:b2474.

    Article  PubMed  Google Scholar 

  3. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–23.

    Article  PubMed  Google Scholar 

  4. Adams LA, Lymp JF, StSauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113–21.

    Article  PubMed  Google Scholar 

  5. Hui JM, Kench JG, Chitturi S, et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology. 2003;38:420–7.

    Article  PubMed  Google Scholar 

  6. Yasui K, Hashimoto E, Komorizono Y, et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011;9:428–33.

    Article  PubMed  Google Scholar 

  7. Bhala N, Angulo P, van der Poorten D, et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology. 2011;54:1208–16.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010;7:195–203.

    Article  PubMed  Google Scholar 

  9. Laurin J. Motion—all patients with NASH need to have a liver biopsy: arguments against the motion. Can J Gastroenterol. 2002;16:722–6.

    PubMed  Google Scholar 

  10. Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2014;20:475–85.

    Article  PubMed Central  PubMed  Google Scholar 

  11. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. Hepatology. 2000;32:477–81.

    Article  CAS  PubMed  Google Scholar 

  12. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128:1898–906.

    Article  PubMed  Google Scholar 

  13. Younossi ZM, Gramlich T, Liu YC, et al. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol. 1998;11:560–5.

    CAS  PubMed  Google Scholar 

  14. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.

    Article  PubMed  Google Scholar 

  15. Fukusato T, Fukushima J, Shiga J, et al. Interobserver variation in the histopathological assessment of nonalcoholic steatohepatitis. Hepatol Res. 2005;33:122–7.

    Article  PubMed  Google Scholar 

  16. Miyaoka H, Michitaka K, Tokumoto Y, et al. Laparoscopic features and interobserver variation of histological diagnosis in patients with non-alcoholic fatty liver disease. Dig Endosc. 2008;20:22–8.

    Article  Google Scholar 

  17. Gawrieh S, Knoedler DM, Saeian K, et al. Effects of interventions on intra- and interobserver agreement on interpretation of nonalcoholic fatty liver disease histology. Ann Diagon Pathol. 2011;15:19–24.

    Article  Google Scholar 

  18. Suzuki A, Angulo P, Lymp J, et al. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int. 2005;25:779–86.

    Article  CAS  PubMed  Google Scholar 

  19. Yoneda M, Mawatari H, Fujita K, et al. Type IV collagen 7 s domain is an independent clinical marker of the severity of fibrosis in patients with nonalcoholic steatohepatitis before the cirrhotic stage. J Gastroenterol. 2007;42:375–81.

    Article  CAS  PubMed  Google Scholar 

  20. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology. 2007;46:32–6.

    Article  CAS  PubMed  Google Scholar 

  21. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846–54.

    Article  CAS  PubMed  Google Scholar 

  22. Harrison SA, Oliver D, Arnold HL, et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008;57:1441–7.

    Article  CAS  PubMed  Google Scholar 

  23. Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology. 2008;47:455–60.

    Article  PubMed  Google Scholar 

  24. Wong VW, Vergniol J, Wong GL, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2010;51:454–62.

    Article  CAS  PubMed  Google Scholar 

  25. Yoneda M, Suzuki K, Kato S, et al. Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography. Radiology. 2010;256:640–7.

    Article  PubMed  Google Scholar 

  26. Ochi H, Hirooka M, Koizumi Y, et al. Real-time tissue elastography for evaluation of hepatic fibrosis and portal hypertension in nonalcoholic fatty liver diseases. Hepatology. 2012;56:1271–8.

    Article  PubMed  Google Scholar 

  27. Kuno A, Ikehara Y, Tanaka Y, et al. A serum “sweet-doughnut” protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep. 2013;3:1065.

    Article  PubMed Central  PubMed  Google Scholar 

  28. Kuno A, Sato T, Shimazaki H, et al. Reconstruction of a robust glycodiagnostic agent supported by multiple lectin-assisted glycan profiling. Proteomics Clin Appl. 2013. doi:10.1002/prca.201300010.

  29. Ito K, Kuno A, Ikehara Y, et al. LecT-Hepa, a glyco-marker derived from multiple lectins, as a predictor of liver fibrosis in chronic hepatitis C patients. Hepatology. 2012;56:1448–56.

    Article  CAS  PubMed  Google Scholar 

  30. Toshima T, Shirabe K, Ikegami T, et al. A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA+ -M2BP), for assessing liver fibrosis. J Gastroenterol. 7 Mar 2014 (Epub ahead of print).

  31. Yamasaki K, Tateyama M, Abiru S, et al. Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients. Hepatology. 12 Jul 2014. doi: 10.1002/hep.27305. (Epub ahead of print).

  32. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–74.

    Article  CAS  PubMed  Google Scholar 

  33. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518–26.

    Article  PubMed  Google Scholar 

  34. Iacobelli S, Arnò E, D’Orazio A, et al. Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer. Cancer Res. 1986;46:3005–10.

    CAS  PubMed  Google Scholar 

  35. Artini M, Natoli C, Tinari N, et al. Elevated serum levels of 90 K/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients. J Hepatol. 1996;25:212–7.

    Article  CAS  PubMed  Google Scholar 

  36. Inohara H, Akahani S, Koths K, et al. Interactions between galectin-3 and Mac-2 binding protein mediate cell-cell adhesion. Cancer Res. 1996;56:4530–4.

    CAS  PubMed  Google Scholar 

  37. Sasaki T, Brakebusch C, Engel J, et al. Mac-2 binding protein is a cell-adhesive protein of the extracellular matrix which self-assembles into ring-like structures and binds beta1 integrins, collagens and fibronectin. EMBO J. 1998;17:1606–13.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  38. Cheung KJ, Tilleman K, Deforce D, et al. The HCV serum proteome: a search for fibrosis protein markers. J Viral Hepat. 2009;16:418–29.

    Article  CAS  PubMed  Google Scholar 

  39. Kamada Y, Fujii H, Fujii H, et al. Serum Mac-2 binding protein levels as a novel diagnostic biomarker for prediction of disease severity and nonalcoholic steatohepatitis. Proteomics Clin Appl. 14 June 2013. doi: 10.1002/prca.201200137. (Epub ahead of print).

  40. Sumida Y, Yoneda M, Hyogo H, et al. Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol. 2012;12:2.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  41. Wong VW, Wong GL, Chim AM, et al. Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis. Am J Gastroenterol. 2008;103:1682–8.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by a Grant-in-Aid from the Ministry of Health, Labour, and Welfare of Japan. This research was performed by the Hepatitis Glyco-biomarker Study Group.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Ehime, 791-0295, Japan

    Masanori Abe, Teruki Miyake & Yoichi Hiasa

  2. Research Center for Medical Glycoscience, National Institute of Advanced Industrial Science and Technology, Tsukuba, Ibaraki, Japan

    Atsushi Kuno & Hisashi Narimatsu

  3. Department of Gastroenterology, Ikeda Municipal Hospital, Ikeda, Osaka, Japan

    Yasuharu Imai & Yoshiyuki Sawai

  4. Department of Hepatology and Pancreatology, Kawasaki Medical School, Kurashiki, Okayama, Japan

    Keisuke Hino & Yuichi Hara

  5. Department of Hepatology, Sapporo-Kosei General Hospital, Sapporo, Hokkaido, Japan

    Shuhei Hige

  6. Department of Pathology, Keio University School of Medicine, Tokyo, Japan

    Michiie Sakamoto

  7. Department of General Internal Medicine 2, Kawasaki Medical School, Kurashiki, Okayama, Japan

    Gotaro Yamada

  8. Department of Diagnostic Pathology, Kurume University Hospital, Kurume, Fukuoka, Japan

    Masayoshi Kage

  9. The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Chiba, Japan

    Masaaki Korenaga & Masashi Mizokami

  10. The Hepatitis Glyco-biomarker Study Group, Tokyo, Japan

    Masanori Abe, Teruki Miyake, Atsushi Kuno, Yasuharu Imai, Yoshiyuki Sawai, Keisuke Hino, Yuichi Hara, Shuhei Hige, Michiie Sakamoto, Masaaki Korenaga, Masashi Mizokami & Hisashi Narimatsu

Authors
  1. Masanori Abe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Teruki Miyake
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Atsushi Kuno
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yasuharu Imai
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoshiyuki Sawai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Keisuke Hino
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yuichi Hara
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shuhei Hige
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Michiie Sakamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Gotaro Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Masayoshi Kage
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Masaaki Korenaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Yoichi Hiasa
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Masashi Mizokami
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Hisashi Narimatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masanori Abe.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 50 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Abe, M., Miyake, T., Kuno, A. et al. Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease. J Gastroenterol 50, 776–784 (2015). https://doi.org/10.1007/s00535-014-1007-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00535-014-1007-2

Keywords

Search

Navigation